3-hydroxy butyrate dehydrogenase 2 deficiency aggravates systemic lupus erythematosus progression in a mouse model by promoting CD40 ligand demethylation

References

• Fortuna G, Brennan MT. Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management. Dent Clin North Am. 2013;57(4):631–655.
   PubMedGoogle Scholar
• Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):825–835.
   PubMed Web of Science ®Google Scholar
• Katsuyama T, Tsokos GC, Moulton VR. Aberrant T cell signaling and subsets in systemic lupus erythematosus. Front Immunol. 2018;9:1088.
   PubMed Web of Science ®Google Scholar
• Goulielmos GN, Zervou MI, Vazgiourakis VM, et al. The genetics and molecular pathogenesis of systemic lupus erythematosus (SLE) in populations of different ancestry. Gene. 2018;668:59–72.
   PubMed Web of Science ®Google Scholar
• Tsai CY, Hsieh SC, Lu CS, et al. Cross-talk between mitochondrial dysfunction-provoked oxidative stress and aberrant noncoding RNA expression in the pathogenesis and pathophysiology of SLE. Int J Mol Sci. 2019;20(20):5183.
   PubMed Web of Science ®Google Scholar
• Tandon A, Anupam K, Kaushal J, et al. Altered oxidative stress markers in relation to T cells, NK cells & killer immunoglobulin receptors that are associated with disease activity in SLE patients. Lupus. 2020;29(14):1831–1844.
   PubMed Web of Science ®Google Scholar
• Strickland FM, Li Y, Johnson K, et al. CD4(+) T cells epigenetically modified by oxidative stress cause lupus-like autoimmunity in mice. J Autoimmun. 2015;62:75–80.
   PubMed Web of Science ®Google Scholar
• Kuhn NF, Purdon TJ, van Leeuwen DG, et al. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell. 2019;35(3):473–488 e6.
   PubMed Web of Science ®Google Scholar
• Karnell JL, Rieder SA, Ettinger R, et al. Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond. Adv Drug Deliv Rev. 2019;141:92–103.
   PubMed Web of Science ®Google Scholar
• Tapia-Llanos R, Munoz-Valle JF, Roman-Fernandez IV, et al. Association of soluble CD40 levels with −1 C > T CD40 polymorphism and chronic kidney disease in systemic lupus erythematosus. Mol Genet Genomic Med. 2019;7(12):e1014.
   PubMed Web of Science ®Google Scholar
• Ramanujam M, Steffgen J, Visvanathan S, et al. Phoenix from the flames: rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis. Autoimmun Rev. 2020;19(11):102668.
   PubMed Web of Science ®Google Scholar
• Zughaier SM, Stauffer BB, McCarty NA. Inflammation and ER stress downregulate BDH2 expression and dysregulate intracellular iron in macrophages. J Immunol Res. 2014;2014:140728.
   PubMed Web of Science ®Google Scholar
• Yang WC, Lin SF, Wang SC, et al. The effects of human BDH2 on the cell cycle, differentiation, and apoptosis and associations with leukemia transformation in myelodysplastic syndrome. Int J Mol Sci. 2020;21(9). https://www.researchgate.net/publication/340975790_The_Effects_of_Human_BDH2_on_the_Cell_Cycle_Differentiation_and_Apoptosis_and_Associations_with_Leukemia_Transformation_in_Myelodysplastic_Syndrome.
   Web of Science ®Google Scholar
• Zhao M, Li MY, Gao XF, et al. Downregulation of BDH2 modulates iron homeostasis and promotes DNA demethylation in CD4(+) T cells of systemic lupus erythematosus. Clin Immunol. 2018;187:113–121.
   PubMed Web of Science ®Google Scholar
• Liang H, Xiong Z, Li R, et al. BDH2 is downregulated in hepatocellular carcinoma and acts as a tumor suppressor regulating cell apoptosis and autophagy. J Cancer. 2019;10(16):3735–3745.
   PubMed Web of Science ®Google Scholar
• Liu JZ, Hu YL, Feng Y, et al. BDH2 triggers ROS-induced cell death and autophagy by promoting Nrf2 ubiquitination in gastric cancer. J Exp Clin Cancer Res. 2020;39(1):123.
   PubMed Web of Science ®Google Scholar
• Kiriakidou M, Ching CL. Systemic lupus erythematosus. Ann Intern Med. 2020;172(11):ITC81–ITC96.
   PubMed Web of Science ®Google Scholar
• Adinolfi A, Valentini E, Calabresi E, et al. One year in review 2016: systemic lupus erythematosus. Clin Exp Rheumatol. 2016;34(4):569–574.
   PubMedGoogle Scholar
• Durcan L, O’Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332–2343.
   PubMed Web of Science ®Google Scholar
• Kavai M, Szegedi G. Immune complex clearance by monocytes and macrophages in systemic lupus erythematosus. Autoimmun Rev. 2007;6(7):497–502.
   PubMed Web of Science ®Google Scholar
• Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity. 2007;40(8):560–566.
   PubMed Web of Science ®Google Scholar
• Sohrabian A, Parodis I, Carlstromer-Berthen N, et al. Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus. Arthritis Res Ther. 2019;21(1):259.
   PubMed Web of Science ®Google Scholar
• Croft M, Siegel RM. Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat Rev Rheumatol. 2017;13(4):217–233.
   PubMed Web of Science ®Google Scholar
• Laman JD, Claassen E, Noelle RJ. Functions of CD40 and its ligand, gp39 (CD40L). Crit Rev Immunol. 2017;37(2–6):371–420.
   PubMed Web of Science ®Google Scholar
• Sharabi A, Tsokos GC. T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy. Nat Rev Rheumatol. 2020;16(2):100–112.
   PubMed Web of Science ®Google Scholar
• Reiche ME, Den Toom M, Willemsen L, et al. Deficiency of T cell CD40L has minor beneficial effects on obesity-induced metabolic dysfunction. BMJ Open Diabetes Res Care. 2019;7(1):e000829.
   PubMed Web of Science ®Google Scholar
• Marken J, Muralidharan S, Giltiay NV. Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients. Arthritis Res Ther. 2021;23(1):5.
   PubMed Web of Science ®Google Scholar
• Puliaev R, Puliaeva I, Welniak LA, et al. CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus. J Immunol. 2008;181(1):47–61.
   PubMed Web of Science ®Google Scholar
• Tang T, Cheng X, Truong B, et al. Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. Pharmacol Ther. 2021;219:107709.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liao J, Zhao M, et al. Increased expression of TLR2 in CD4(+) T cells from SLE patients enhances immune reactivity and promotes IL-17 expression through histone modifications. Eur J Immunol. 2015;45(9):2683–2693.
   PubMed Web of Science ®Google Scholar
• He J, Zhang X, Wei Y, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22(9):991–993.
   PubMed Web of Science ®Google Scholar
• Wang H, Liu C, Chen W, Ding, G . The skewed frequency of B-cell subpopulation CD19(+) CD24 (hi) CD38 (hi) cells in peripheral blood mononuclear cells is correlated with the elevated serum sCD40L in patients with active systemic lupus erythematosus. J Cell Biochem. 2019.
   Web of Science ®Google Scholar
• Perper SJ, Westmoreland SV, Karman J, et al. Treatment with a CD40 antagonist antibody reverses severe proteinuria and loss of saliva production and restores glomerular morphology in murine systemic lupus erythematosus. J Immunol. 2019;203(1):58–75.
   PubMed Web of Science ®Google Scholar
• Zhao M, Liu Q, Liang G, et al. E4BP4 overexpression: a protective mechanism in CD4+ T cells from SLE patients. J Autoimmun. 2013;41:152–160.
   PubMed Web of Science ®Google Scholar
• Oxer DS, Godoy LC, Borba E, et al. PPARgamma expression is increased in systemic lupus erythematosus patients and represses CD40/CD40L signaling pathway. Lupus. 2011;20(6):575–587.
   PubMed Web of Science ®Google Scholar
• Guo K, Lukacik P, Papagrigoriou E, et al. Characterization of human DHRS6, an orphan short chain dehydrogenase/reductase enzyme: a novel, cytosolic type 2 R-beta-hydroxybutyrate dehydrogenase. J Biol Chem. 2006;281(15):10291–10297.
   PubMed Web of Science ®Google Scholar
• Yang WC, Tsai WC, Lin PM, et al. Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia. J Biomed Sci. 2013;20:58.
   PubMed Web of Science ®Google Scholar